A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia

Biological Psychiatry

Volumn 43, Issue 11, 1998, Pages 803-810

  Tollefson, Gary D ^a   Sanger, Todd M ^a   Beasley, Charles M ^a   Tran, Pierre V ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Anxiety; Depression; Haloperidol; Olanzapine; Schizophrenia

Indexed keywords

DOPAMINE; DOPAMINE RECEPTOR BLOCKING AGENT; HALOPERIDOL; NEUROLEPTIC AGENT; NORADRENALIN; OLANZAPINE; PROLACTIN; SEROTONIN;

ADULT; AGED; ANXIETY NEUROSIS; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PREFRONTAL CORTEX; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; ANXIETY; BENZODIAZEPINES; DEPRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HALOPERIDOL; HUMANS; MALE; MIDDLE AGED; PIRENZEPINE; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 0032103130     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(98)00093-6     Document Type: Article

References (53)

1. Barnes T.R. A rating scale for drug-induced akathisia. Br J Psychiatry. 154:1980;672-676.
2. Beasley C.M. Jr, Tollefson G.D., Tran P.V., Satterlee W.G., Sanger T.M., Hamilton S. Olanzapine versus placebo and haloperidol. Acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology. 14:1996;111-123.
3. Becker R.E. Depression in schizophrenia. Hosp Community Psychiatry. 39:1988;1269-1274.
4. Birchwood M., Mason R., Macmillan F., Healy J. Depression, demoralization and control over psychotic illness A comparison of depressed and non-depressed patients with a chronic psychosis . Psychol Med. 23:1993;387-395.
5. Black D.W., Winokur G., Warrock G. Suicide in schizophrenia The Iowa record linkage study . J Clin Psychiatry. 46:1985;14-17.
6. Bleuler E. Dementia Praecox or the Group of Schizophrenias. 1950;International Universities Press, New York.
7. Bymaster F.P., Calligaro D.O., Falcone J.F., Marsh R.D., Moore N.A., Tye N.C., et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology. 14:1996;87-96.
8. Caldwell C.B., Gottesman I.I. Schizophrenics kill themselves too A review of risk factors for suicide . Schizophr Bull. 16:1990;571-589.
9. Carlsson A. Neurocircuitries and neurotransmitter interactions in schizophrenia. Int Clin Psychopharmacol. 10:(suppl 3):1995;21-28.
10. Chouinard G., Jones B.D. Schizophrenia as a depressive deficiency disease. Lancet. ii:1978;99-100.
11. Corbett R., Camacho F., Woods A.T., Kerman L.L., Fishkin R.J., Brooks K., et al. Antipsychotic agents antagonize non-competitive N-methyl-D-aspartate antagonist-induced behaviors. Psychopharmacology (Berl). 120:1995;67-74.
12. Craig T.J., Richardson M.A., Pass R., Bregman Z. Measurement of mood and affect in schizophrenic inpatients. Am J Psychiatry. 142:1985;1272-1277.
13. Deutch A.Y., Moghaddam B., Innis R.B., Krystal J.H., Aghajanian G.K., Bunney B.S., et al. Mechanisms of action of atypical antipsychotic drugs Implications for novel therapeutic strategies for schizophrenia . Schizophr Res. 4:1991;121-156.
14. Falloon I., Watt D.C., Shepherd M. A comparative controlled trial of pimozide and fluphenazine decanoate in the continuation therapy of schizophrenia. Psychol Med. 8:1978;59-70.
15. Galdi J. The causality of depression in schizophrenia. Br J Psychiatry. 142:1983;621-625.
16. Garver D.L., Kelly K., Fried K.A., Magnusson M., Hirschowitz J. Drug response patterns as a basis of nosology for mood-incongruent psychoses (the schizophrenias). Psychol Med. 18:1988;873-885.
17. Guy W. ECDEU Assessment Manual for Psychopharmacology, rev. 1976;US Department of Health, Education and Welfare, Bethesda, MD.
18. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol. 6:1967;278-296.
19. Harrow M., Yonan C.A., Sands J.R., Marengo J. Depression in schizophrenia Are neuroleptics, akinesia, or ankedonia involved? Schizophr Bull. 20:1994;327-338.
20. Hirsch S.R., Jolley A.G. The dysphoric syndrome in schizophrenia and its implications for relapse. Br J Psychiatry. 155:(suppl 5):1989;46-50.
21. Hogarty G.E., McEvoy J.P., Ulrich R.F., DiBarry A.L., Bartone P., Cooley S., et al. Pharmacotherapy of impaired affect in recovering schizophrenic patients. Arch Gen Psychiatry. 52:1995;29-41.
22. Johnson D.A.W. The significance of depression in the prediction of relapse in chronic schizophrenia. Br J Psychiatry. 152:1988;320-323.
23. Kinon B.J., Lieberman J.A. Mechanisms of action of atypical antipsychotic drugs A critical analysis . Psychopharmacology (Berl). 124:1996;2-34.
24. Knights A., Hirsch S.R. 'Revealed' depression and drug treatment for schizophrenia. Arch Gen Psychiatry. 38:1981;806-811.
25. Krakowski M., Czobor P., Volavka J. Effect of neuroleptic treatment on depressive symptoms in acute schizophrenic episodes. Psychiatry Res. 71:1997;19-26.
26. Kramer M.S., Vogel W.H., DiJohnson C., Dewey D.A., Sheves P., Cavicchia S., et al. Antidepressants in 'depressed' schizophrenic inpatients. Arch Gen Psychiatry. 46:1989;922-928.
27. Leff J., Tress K., Edwards B. The clinical course of depressive symptoms in schizophrenia. Schizophr Res. 1:1988;25-30.
28. Lindenmayer J.P., Kay S.R., Friedman C. Negative and positive schizophrenic syndromes after the acute phase A prospective follow-up . Compr Psychiatry. 27:1986;276-286.
29. Martin R.L., Cloninger C.R., Guze S.B., Clayton P.J. Frequency and differential diagnosis of depressive syndromes in schizophrenia. J Clin Psychiatry. 46:1985;9-13.
30. Meltzer H.Y. The mechanism of action of novel antipsychotic drugs. Schizophr Bull. 17:1991;263-287.
31. Meltzer H.Y. Serotonin-dopamine interactions and atypical antipsychotic drugs. Psychiatric Ann. 23:1993;193-200.
32. Möller H.J., vonZerssen D. Depression in schizophrenia. In: Burrows GD, Norman TR, Rubinstein G, editors. Handbook of Studies on Schizophrenia, part 1. 1986;183-191 Elsevier, Amsterdam.
33. Montgomery S.M. Depressive symptoms in acute schizophrenia. Prog Neuropsychopharmacol. 3:1979;429-433.
34. Moore N.A., Rees G., Sanger G., Tye N.C. Effects of olanzapine and other antipsychotic agents on responding maintained by a conflict schedule. Behav Pharmacol. 5:1994;196-202.
35. Overall J.E. The brief psychiatric rating scale in psychopharmacology research. Pichot P. Psychological Measurements in Psychopharmacology. Modern Problems in Pharmacopsychiatry. 1974;67-78 Karger, Basel.
36. Overall J.E., Gorham D.R. The brief psychiatric rating scale. Psychol Rep. 10:1962;799-812.
37. Pickar D., Owen R.R., Litman R.E., Konicki E., Gutierrez R., Rapaport M.H. Clinical and biologic response to clozapine in patients with schizophrenia. Arch Gen Psychiatry. 49:1992;345-353.
38. Pogue-Geile M.F., Harrow M. Negative and positive symptoms in schizophrenia and depression A follow-up . Schizophr Bull. 10:1984;371-387.
39. SAS Institute (1990): SAS/STAT User's Guide, vols 1 and 2, 4th ed, 6th version. Cary, NY: SAS Institute.
40. Seeman P., Van Tol H.H.M. Dopamine receptor pharmacology. Curr Opin Neurol Neurosurg. 6:1993;602-608.
41. Simpson G.M., Angus J.W. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 212:1970;11-19.
42. Siris S.G. Depression and schizophrenia. Hirsch S.R., Weinberger D.R. Schizophrenia. 1995;128-145 Blackwell Science Inc, Cambridge, MA.
43. Spina E., DeDomenico P., Ruello C., Longobardo N., Gitto C., Ancione M., et al. Adjunctive fluoxetine in the treatment of negative symptoms in chronic schizophrenic patients. Int Clin Psychopharmacol. 9:1994;281-285.
44. Stockton M.E., Rasmussen K. Olanzapine, a novel atypical antipsychotic, reverses d-amphetamine-induced inhibition of mid-brain dopamine cells. Psychopharmacology (Berl). 124:1996;50-56.
45. Tandon R., Greden J.F. Cholinergic hyperactivity and negative schizophrenic symptoms A model of cholinergic-dopaminergic interactions in schizophrenia . Arch Gen Psychiatry. 46:1989;745-753.
46. Tollefson G.D., Sanger T.M. Negative symptoms A path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine . Am J Psychiatry. 154:1997;466-474.
47. Tollefson G.D., Sanger T.M., Lu Y., Thieme M.E. Depressive signs and symptoms in schizophrenia - A prospective blinded trial of olanzapine and haloperidol. Arch Gen Psychiatry. 55:1998;250-258.
48. Tollefson G.D., Beasley C.M. Jr, Tran P.V., Street J.S., Krueger J.A., Tamura R.N., et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders Results of an international collaborative trial . Am J Psychiatry. 154:1997;457-465.
49. Van Putten T., May, Ra. Akinetic depression in schizophrenia. Arch Gen Psychiatry. 35:1978;1102-1107.
50. Waehrens J., Gerlach J. Antidepressant drugs in anergic schizophrenia A double-blind cross-over study with maprotiline and placebo . Acta Psychiatry Scand. 61:1980;438-444.
51. Williams R., Dalby J.T. Drug and subject influences on measures of depression and negative symptoms in schizophrenic patients. Williams R., Dalby J.T. Depression in Schizophrenics. 1989;244-253 Plenum Publishing Corporation, New York.
52. Wise R.A. Neuroleptics and operant behavior The anhedonia hypothesis . Behav Brain Sci. 5:1982;39-87.
53. Xi-Ming L., Perry K.W., Wong D.T., Bymaster F.P. Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum. Psychopharmacology (Berl). 136:1998;153-161.